Expansion of Overseas Sales Activities

「Owing to increased overseas sales of the flagship ELISA kits and higher sales of the bovine spongiform encephalopathy testing kit (BSE kit), an in vitro diagnostic product for veterinary use, among other factors」

「Revenue from this service increased year on year, supported by the continued adoption of the Company’s flagship ELISA kits in clinical trials conducted by overseas CROs, increased domestic sales of antibodies used as raw materials for in vitro diagnostic products, and steady sales of contract services and other offerings.」

「Although sales of veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kits (BSE kits) declined, revenue from this service increased substantially year on year due to factors including higher overseas sales of the core ELISA kits and substantial antibody sales for raw materials for in vitro diagnostic products. Sales of contract services also increased. As a result, revenue from this service increased 14.8% year on year to ¥415.178 million.」

「The antibody-related business increased 2.8% year on year to ¥812,850 thousand, mainly because sales of its core ELISA kits and antibodies expanded through an information strategy using e-marketing in overseas sales and the benefits of the weaker yen.」

「Overseas sales increased substantially from the previous year because Angiotensinogen (AGT) ELISA and Gd-IgA1 ELISA were adopted for clinical trials by overseas CRO companies and because of several large antibody sales transactions.」

「The antibody-related business increased 2.8% year on year to ¥812,850 thousand, mainly because sales of its core ELISA kits and antibodies expanded through an information strategy using e-marketing in overseas sales and the benefits of the weaker yen.」

「Sales of the service’s core products, ELISA kits and antibodies, increased both in Japan and overseas from the previous year, as did contract services related to reagents.」

「Sales volumes of the Company’s core ELISA kits and antibodies increased substantially as its information strategy using e-marketing, including social media, for overseas sales increased inquiries from researchers at major overseas CROs, pharmaceutical companies and universities. Revenue also increased substantially year on year due to the weaker yen.」

「The results of the information strategy using e-marketing, including social media, have begun to emerge in overseas sales activities, and the number of core ELISA kits and antibodies sold overseas increased substantially from the previous year.」

「The results of the information strategy using e-marketing, including social media, have begun to emerge in overseas sales activities, and overseas sales of the core ELISA kits and antibodies increased substantially from the previous year.」

「Sales in this business benefited from the recording of sales of a veterinary in vitro diagnostic bovine spongiform encephalopathy measurement kit (BSE kit), as well as the initial results of an information strategy using e-marketing, including social media, in overseas sales activities. Sales of the core EIA measurement kits and antibodies overseas increased substantially from the previous year.」

「Sales in this business increased as research and development activities at companies, universities and other institutions became more active. Orders for the core EIA measurement kits and antibodies in Japan and overseas continued steadily, with sales increasing each quarter.」

「Sales from the third quarter onward are expected to increase substantially, including sales of contract-manufactured products, veterinary in vitro diagnostics and diagnostic reagent antibodies for overseas markets.」

「Revenue from research reagents, including the Company’s core EIA kits and antibodies, declined by approximately 30% year on year as customers in Japan and overseas curtailed their research and business activities due to the spread of COVID-19.」

「Overseas sales of the core EIA kit increased steadily through the previous fiscal year as the distributor network was strengthened, but declined substantially this fiscal year due to the completion of a large-scale project for a CRO and other factors.」

「Sales of research reagents increased year on year because antibody products generated relatively large transactions. In contrast, overseas sales of the core EIA kit declined substantially due to the completion of a large-scale project for a CRO and other factors, while domestic sales also declined substantially because of stagnation in the reagent market, delays in launching new products and other factors.」

「Overseas sales of the core EIA kit declined substantially from the previous year due to the completion of a large-scale project for a CRO and other factors,」

「The Company’s active participation in overseas academic conferences and increased opportunities for communication with academia and distributors proved effective, expanding its overseas distributor network to 13 companies, including in Asia and Europe. As a result, overseas sales in the segment clearly increased 31% from the previous fiscal year.」

「The Company focused on building relationships with overseas customers, actively participating in academic conferences and other events, and signing agreements with new distributors, substantially increasing overseas sales during the third quarter of the current fiscal year. Sales in this business have fluctuated due to research themes in Japan and have been unstable in some respects, but the gradual expansion of overseas sales has made stable sales achievable. The Company will continue to focus on overseas sales and seek stable management. As a result, segment sales were ¥430,267 thousand, up 7.9% year on year, and operating profit was ¥88,502 thousand, up 36.3%.」

「In research reagents, sales of the core antibody-related products declined in Japan. Overseas, however, the Company focused on building relationships with customers, actively participating in academic conferences and other events, and signing agreements with new distributors. As a result, the increase in overseas sales became clearly evident during the second quarter of the current fiscal year. Sales in this business have shown some seasonal fluctuations and instability due to research themes in Japan, but the gradual expansion of overseas sales has made stable sales achievable. The Company will continue to focus on overseas sales and seek stable management. As a result, segment sales were ¥265,690 thousand, up 1.5% year on year, and operating profit was ¥42,072 thousand, down 8.7%.」

「In research reagents, the Company focused on building relationships with overseas customers, actively participating in overseas academic conferences and other events, and signing agreements with new distributors. These efforts produced results, with sales increasing substantially year on year during the first quarter of the current fiscal year. As a result, segment sales were ¥135,435 thousand, up 33.9% year on year, and operating profit was ¥15,795 thousand, compared with an operating loss of ¥9,850 thousand in the same period of the previous year.」

「The effects are now clearly evident in the form of increases in the number of business partners, operating regions and sales. Sales were ¥605,745 thousand, up 8.9% from the same period of the previous year, while operating profit was ¥127,506 thousand, up 8.2%, resulting in higher sales and profit.」

「The business actively conducted promotional activities through academic conference exhibitions in Japan and overseas, increased orders for large-scale projects and other engagements, and achieved a substantial year-on-year increase in sales.」

「For research-related products, the Company plans to actively promote its products overseas, secure reliable overseas partners and expand the overseas sales network for its proprietary antibody and kit products.」

「LipoSEARCH, the business’s core contract service for analyzing detailed profiling data on blood lipoprotein fractions using a system based on gel-filtration HPLC, actively conducted promotional activities at overseas academic conferences, expanded its overseas customer base and achieved a substantial increase in sales.」

「Regarding overseas sales, the Group began full-scale promotional activities at overseas academic conferences during the current fiscal year, and sales have been increasing steadily.」

「The Company is actively conducting promotional activities overseas through exhibitions at academic conferences, raising expectations for securing orders going forward.」

「Overseas, the Company has established a dedicated department and is conducting sales activities for the entire Group, including Alzheimer’s disease-related products, while promoting products in a wide range of fields internationally.」